RTOG 96-10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck

Keyphrases

• Head-and-neck 100%
• 1-year Survival 100%
• 5-fluorouracil (5-FU) 100%
• Head-and-neck Cancer 100%
• Hydroxyurea 100%
• Squamous Cell Cancer 100%
• Re-irradiation 100%
• Second Primary 50%
• Systemic Chemotherapy 50%
• Neutropenia 25%
• Spinal Cord 25%
• Twice Daily 25%
• Bolus 25%
• Median Overall Survival 25%
• Objective Response Rate 25%
• Thrombocytopenia 25%
• Radiation Dose 25%
• Concurrent Chemotherapy 25%
• Treatment Toxicity 25%
• Living Patients 25%
• Measurable Disease 25%
• Tumor Volume 25%
• Tumor Site 25%
• Therapeutic Impact 25%
• Mucositis 25%
• Eligibility Requirements 25%
• Weekly Cycle 25%
• Irradiated Patients 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Survival Rate 100%
• Squamous Cell Carcinoma 100%
• Fluorouracil 100%
• Hydroxycarbamide 100%
• Chemotherapy 75%
• Neoplasm 50%
• Recurrent Disease 50%
• Overall Survival 25%
• Neutropenia 25%
• Thrombocytopenia 25%
• Bleeding 25%
• Mucosa Inflammation 25%
• Diseases 25%

Nursing and Health Professions

• Survival Rate 100%
• Fluorouracil 100%
• Squamous Cell Carcinoma 100%
• Recurrent Disease 50%
• Neutropenia 25%
• Bleeding 25%
• Overall Survival 25%
• Neoplasm 25%
• Thrombocytopenia 25%
• Radiation Dose 25%
• Tumor Volume 25%
• Diseases 25%